Ex-Pfiz­er staffer found guilty of in­sid­er trad­ing af­ter buy­ing stock op­tions a day be­fore Paxlovid da­ta re­veal

A for­mer Pfiz­er em­ploy­ee was found guilty of buy­ing stock op­tions a day be­fore the com­pa­ny un­veiled pos­i­tive Covid-19 drug da­ta.

Amit Da­gar was a se­nior sta­tis­ti­cal pro­gram lead for the clin­i­cal tri­al of Paxlovid, Pfiz­er’s Covid an­tivi­ral, per an SEC doc­u­ment.

On Nov. 4, 2021, up­on learn­ing that the Paxlovid study yield­ed pos­i­tive re­sults, Da­gar bought Pfiz­er call op­tions, ac­cord­ing to fed­er­al pros­e­cu­tors. He then in­formed a friend, who al­so bought com­pa­ny call op­tions, be­fore the re­sults were to be made pub­lic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.